Zimmer Spine has concluded a deal through which it will distribute Benvenue Medical's Kiva VCF treatment system. The system, which has CE Mark approval, is used to treat vertebral compression fractures.
The system will initially be distributed in Germany and Italy and will reach a broader audience throughout the EU shortly. The minimally invasive VCF market in the EU was estimated to be $185 million in 2010, according to a statement.
"The Kiva System represents Zimmer Spine's first VCF product offering for our customers. This differentiated VCF system is a natural extension to our existing product lines," explains Hubert Piatkowski, VP, Zimmer Spine, in a statement.
Kiva is being evaluated against balloon kyphoplasty in VCFs in the KAST study at three sites in Europe. KAST is the largest randomized study versus balloon kyphoplasty to date and is being conducted in support of a future 510(k) market clearance in the U.S. Earlier this year, Benvenue snagged $35.5 milllion in a Series C financing round to continue the study.
- check out the Zimmer/Benvenue Medical release
Special Report: Benvenue Medical - Top 10 medical device VC deals, H1 2011